Castle Biosciences (NASDAQ: CSTL) reported quarterly losses of $(0.49) per share which met the analyst consensus estimate. This is a 145 percent decrease over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $83.700 million which beat the analyst consensus estimate of $79.415 million by 5.40 percent. This is a 4.89 percent decrease over sales of $88.000 million the same period last year.